AMTD International raised $174M in its initial public offering, with shares rising 20% in the company's debut day on the NYSE.
InMode (INMD) opened on August 8 at $13.50. The company had priced 5M shares at $14.00, at the low end of $14.00-$16.00 target range. Barclays and UBS acted as joint book running managers for the offering. InMode develops energy-based, minimally-invasive surgical aesthetic and medical treatment solutions.
AMTD International (HKIB) opened on August 5 at $8.91. The company had priced 20.8M shares at $8.38. The deal range was $8.10-$8.48. AMTD Global Markets Limited and Loop Capital Markets were the lead underwriters of this offering, with the support of other underwriters. AMTD International is a subsidiary of AMTD Group and ranks as Asia's largest independent investment banking firm and the largest for PRC regional banks and new economy companies.
- In its first trading day, InMode ended at $13.57.
- AMTD International opened higher and finished the week at $9.90.
UPCOMING IPOS: Among the upcoming IPOs are Biovie (BIVI) and CrossFirst Bankshares (CFB).
Biovie is a clinical-stage company focused on the development of BIV201, its novel treatment of ascites due to chronic liver cirrhosis. On August 5, the last reported sale price for the company's common stock as reported on the OTCQB Marketplace was $11.44 per share, after giving effect to the company's planned 1:125 reverse stock split. "The final public offering price will be determined through negotiation between us and the lead underwriters in the offering and the recent market price used throughout this prospectus may not be indicative of the final offering price," Biovie stated in its offering prospectus.
CrossFirst Bankshares is a Kansas corporation and a registered bank holding company for its wholly-owned subsidiary CrossFirst Bank. CrossFirst Bank has seven full-service banking offices primarily along the I-35 corridor in Kansas, Missouri, Oklahoma and Texas.
"Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, analyst commentary and upcoming IPOs.